Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Clinical trial NCT04109066 · COMPLETED
Trial details
- NCT number
- NCT04109066
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-18
- Primary completion
- 2023-01-16
- Enrollment
- 521
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.